Skip to main content

Table 4 Summary by frequency of AEs of any severity, felt to possibly, likely, or almost certainly caused by injection of vaccines

From: Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses

Adverse Event

All (N = 42)

TCV (n = 24)

DCV (n = 18)

P value

Injection site reactions

28 (67%)

16 (67%)

12 (67%)

1.00

Flu-like symptoms

14 (33%)

9 (38%)

5 (28%)

0.742

Nausea

8 (19%)

5 (21%)

3 (17%)

1.00

Bone discomfort

7 (17%)

4 (17%)

3 (17%)

1.00

Headache

6 (14%)

3 (12%)

3 (17%)

1.00

Fatigue

5 (12%)

5 (21%)

0 (0%)

0.060

Chills

5 (12%)

1 (4%)

4 (22%)

0.146

Pruritus

3 (7%

2 (8%)

1 (6%)

1.00

Arthralgias

3 (7%)

1 (4%)

2 (11%)

0.567

Fever

3 (7%)

3 (12%)

0 (0%)

0.247

Rash

2 (5%)

2 (8%)

0 (0%)

0.498

Hives (urticarial)

2 (5%)

2 (8%)

0 (0%)

0.498

Shingles

2 (5%)

2 (8%)

0 (0%)

0.498

Myalgias

1 (2%)

0 (0%)

1 (6%)

0.429

  1. TCV tumor cell vaccine, DCV dendritic cell vaccine